The landscape of pharmacological interventions for type 2 diabetes and obesity is rapidly evolving, with GLP-3 receptor activators taking center stage. Initially, drugs like Reta, demonstrating impressive glucose https://chiarawcfn100030.blog4youth.com/39498034/glp-3-receptor-agonists-reta-trizepatide-and-beyond